Bullish Views for XPeng and Blueprint Medicines
- August 21st, 2023
- 329 views
XPeng Inc. (NYSE: XPEV), a leading Chinese electric vehicle manufacturer, received a boost in investor sentiment as BofA Securities upgraded the company from Neutral to Buy and raised the price target from $16.30 to $22.00.
Considering that $XPEV closed at $14.98 on Friday, the adjusted price target indicates a potential upside of $7.02 or approximately 46.83%, based on the financial advisory firm's assessment
In other news, Blueprint Medicines Corporation (Nasdaq: BPMC) continues to receive a favorable evaluation from Needham, as the brokerage firm maintained its Buy rating and raised the price target from $65 to $66.
Based on Friday's closing price of $49.29, the updated price target implies a potential upside of $16.71 or approximately 33.88% for $BPMC, according to Needham's analysis.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Micron Technology, Jabil, and Birkenstock Earnings Preview: What to Expect
December 15th, 2024Upcoming Earnings: Synopsys, AeroVironment, and nCino in Focus
December 01st, 2024Countdown to Earnings: Salesforce, Marvell Technology, and Okta Take the Stage
December 01st, 2024Fluence Energy, Agilent Technologies, and Woodward Earnings On Deck: A Preview
November 24th, 2024Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024
Member Login